Fischer Medical Ventures Ltd

The provided transcript does not mention any current or planned fundraising activities through debt or equity by Fischer Medical Ventures Limited. Key points related to financial status include: - The company maintains a strong balance sheet with net cash of INR 28 crores and a low debt-to-equity ratio of 0.04, indicating comfortable leverage. - No explicit discussion or announcements of new debt or equity fundraising were made during the Q2 FY '26 earnings call. - Management emphasized cost optimization and operational leverage rather than external financing for growth. - Expansion plans focus on capacity scaling and product development, with no mention of raising capital via fundraising. Therefore, based on the transcript, there is no indication of any ongoing or forthcoming fundraising through debt or equity.

- Current manufacturing capacity: About 80 MRI machines per year in one shift; can be increased to 150-160 with two shifts. - Facility expansion plans underway: Expansion of manufacturing facility to include other imaging lines such as CT scanners. - Preventive healthcare capacity expansion: Focus on people (AI, software development) and server infrastructure rather than hardware manufacturing. - Supply chain and regulatory focus: Continued efforts on obtaining international regulatory approvals for exports; current emphasis remains on domestic market. - No specific capex amounts disclosed, but expansion and capacity scaling are actively planned and in process, including brownfield expansion options. - Plans to scale AI and tele-diagnostic solutions as part of preventive healthcare ecosystem development.

- Fischer Medical Ventures targets a 15%-20% market share in the domestic and Asian MRI markets within 2-3 years, supported by a strong order book and favorable government policies. - The total addressable market (TAM) for MRI devices in India is around 500 units per year, expected to grow over 1000 units annually in 3-4 years, driven by government health missions. - Growth is expected to be broad-based across Radiology (MRI and CT) and Preventive Healthcare segments, with revenue contribution expected to be almost equally split between these two in 2-3 years. - Company aims to leverage Make-In-India and Atmanirbhar Bharat initiatives along with import substitution to drive growth aligned with sector CAGR of 15%-20%. - Export markets are growing, contributing about 30% of revenues currently, up from about 5-10% a year ago, indicating international expansion potential. - Capacity can scale from 80 MRI machines/year (one shift) to about 150-160 machines/year (two shifts) to meet demand.

- Fischer Medical Ventures expects to sustain growth aligned with the MedTech industry's macro growth rate of 15-20% CAGR, driven by government policies favoring Make-In-India and Atmanirbhar Bharat initiatives. - Revenue split between Imaging and Preventive Healthcare segments is expected to become almost equal in 2-3 years, contributing significantly to overall growth. - The company highlights strong operating leverage and cost optimization strategies that have improved EBITDA margins notably (21% in the recent quarter). - While no explicit earnings guidance is provided, the company projects continued strong order books, especially in MRI machines, and revenue growth fueled by domestic and export markets. - PAT has improved tremendously (107x YoY in H1 FY '26), signaling profitability momentum likely to continue. - Expansion plans include scaling manufacturing capacity and entering CT and interoperable MRI markets, supporting future earnings growth. - The company avoids providing specific forward-looking profit or EPS numbers but indicates confident growth prospects in line with sector trends.

- Fischer Medical Ventures has a strong order book currently. - Orders are being fulfilled as and when they arise, especially in the MRI segment. - The sales cycle for MRI machines ranges from 6 to 9 months, sometimes up to 12 months. - The company expects good order inflow for the rest of H2 FY '26 and into the next year. - Exact figures of the backlog are not disclosed due to customer confidentiality. - Overall, the company is confident about fulfilling a robust order book through the near term.